Physician profile
Jennifer Eads
NPI 1487842100
$42,809.51
in general payments reported to CMS, 2019-2025
19 companies · $26K in 2025
The $26K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $5,885 · 2022: $400 · 2023: $2,161 · 2024: $6,531 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Honoraria: $7,800 · Travel and Lodging: $4,050 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,430 · Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,805.00 |
| Honoraria | $7,800.00 |
| Travel and Lodging | $4,049.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,430.00 |
| Food and Beverage | $1,013.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $11,328.25 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $10,045.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $4,800.00 | 2025 | Imfinzi |
| Tersera Therapeutics LLC | $3,541.01 | 2025 | Xermelo |
| Eli Lilly and Company | $2,737.00 | 2025 | |
| Advanced Accelerator Applications | $2,500.00 | 2020 | |
| Lantheus Medical Imaging, INC. | $2,430.00 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $1,750.00 | 2020 | |
| Pfizer INC. | $1,500.00 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $1,426.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $224.53 | 2022 | |
| Celularity INC. | $175.56 | 2022 | |
| Delcath Systems | $161.18 | 2025 | Hepzato Kit |
| Astrazeneca Ab | $134.99 | 2020 | |
| Caris Mpi, INC. | $29.24 | 2025 | Mi Cancer Seek |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $25.77 | 2023 | Monarch Platform |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Eads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.